Fareston Toremifene: Side Effects, Uses, Dosage, Interactions, Warnings

The administration of FARESTON with agents that have demonstrated QT prolongation as one of their pharmacodynamic effects should be avoided. Should treatment with any of these agents be required, it is recommended that therapy with FARESTON be interrupted. If interruption of treatment with FARESTON is not https://www.firstsmiledds.com/legal-alternatives-to-steroids-exploring-safer/ possible, patients who require treatment with a drug that prolongs QT should be closely monitored for prolongation of the QT interval. In patients at increased risk, electrocardiograms (ECGs) should be obtained and patients monitored as clinically indicated [see BOX WARNING and WARNINGS AND PRECAUTIONS].

Keep a list of all the products you use (including prescription/nonprescription drugs and herbal products) and share it with your doctor and pharmacist. Do not start, stop, or change the dosage of any medicines without your doctor’s approval. Toremifene is used in postmenopausal women to treat breast cancer. It is usually used to treat cancer that needs estrogen, a hormone, in order to grow (estrogen-receptor positive).

If you become pregnant or think you may be pregnant, inform your doctor right away. Women of childbearing age should use reliable forms of non-hormonal birth control (such as condoms, diaphragm with spermicide) while using this medication. Discuss the use of birth control, the risks and benefits of this medication, and any other concerns about using this medication with your doctor. Tell your doctor right away if you develop changes in menstrual period, unusual vaginal bleeding/discharge or pain/pressure below your “belly button” (navel). Avoid eating grapefruit or drinking grapefruit juice while using this medication unless your doctor or pharmacist says you may do so safely.

  • If hypercalcemia occurs, appropriate measures should be instituted and, if hypercalcemia is severe, FARESTON treatment should be discontinued.
  • As a result, the amount of estrogen that the tumor is exposed to is reduced, which will limit the growth of the tumor.
  • If any of these side effects last or get worse, tell your doctor promptly.
  • Its effectiveness, safety profile, and potential for usage as a substitute for other SERMs, such as tamoxifen, are all subjects of research.

Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. Data sources include Micromedex (updated 3 Mar 2024), Cerner Multum™ (updated 17 Mar 2024), ASHP (updated 20 Mar 2024) and others. This includes prescription and over-the-counter medicines, vitamins, and herbal products.

6 Effect of Toremifene on CYP2C9 Substrates

Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Serious adverse reactions occurring in at least 1% of patients receiving FARESTON in the three major trials are listed in the table below. Our Fareston (toremifene citrate) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication. Research shows that toremifene can prevent prostate cancer in men who are at high risk.

Take it as directed on the prescription label at the same time every day. This medicine may be used for other purposes; ask your health care provider or pharmacist if you have questions. Patients who must take medications known to prolong the QT interval, or potent CYP3A4 inhibitors, should be informed of the effect of toremifene on QT interval. Toremifene has been shown to prolong the QTc interval in a dose-related manner [see BOX WARNING, WARNINGS AND PRECAUTIONS, and CLINICAL PHARMACOLOGY]. Premenopausal women using FARESTON should use nonhormonal contraception during treatment and should be apprised of the potential hazard to the fetus should pregnancy occur [see WARNINGS AND PRECAUTIONS]. The pharmacokinetics of toremifene and N-demethyltoremifene were similar in normals and patients with impaired kidney function.

What side effects may I notice from receiving this medication?

In animal studies, toremifene crossed the placenta and accumulated in the rodent fetus. Fetal anomalies include malformation of limbs, incomplete ossification, misshapen bones, ribs/spine anomalies, hydroureter, hydronephrosis, testicular displacement, and subcutaneous edema. Maternal toxicity may have contributed to these adverse embryo-fetal effects. Similar embryo-fetal toxicities occurred in rabbits that received toremifene at doses approximately 40% the daily recommended human dose of 60 mg (on a mg/m2 basis). Findings in rabbits included increased preimplantation loss, increased resorptions, and fetal anomalies, including incomplete ossification and anencephaly. For the treatment of metastatic breast cancer in postmenopausal women with estrogen receptor-positive or receptor-unknown tumors.

What should I tell my care team before I take this medication?

Two of the 3 studies showed similar results for all effectiveness endpoints. However, the Nordic Study showed a longer time to progression for tamoxifen (see table). Animal doses resulting in embryo-fetal toxicities were ≥1.0 mg/kg/day in rats and ≥1.25 mg/kg/day in rabbits.